|
Market Closed -
OTC Markets
14:55:52 2026-09-11 EDT
|
5-day change | 1st Jan Change | ||
| 2.820 USD | +3.75% |
|
0.00% | -17.78% |
| 08-12 | HLS Therapeutics Inc., Q2 2026 Earnings Call, Aug 12, 2026 | |
| 08-12 | HLS Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: HLS Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 384.6 | 235.2 | 95.92 | 86.84 | 109.9 | 86.34 | - | - |
| Change | - | -38.85% | -59.22% | -9.47% | 26.6% | -21.46% | - | - |
| Enterprise Value (EV) | 384.6 | 235.2 | 95.92 | 86.84 | 109.9 | 86.34 | 86.34 | 86.34 |
| Change | - | -38.85% | -59.22% | -9.47% | 26.6% | -21.46% | 0% | 0% |
| P/E | -28.9x | -9.95x | -3.52x | -4.41x | -9.01x | -13.5x | -39.9x | 31x |
| PBR | - | 1.88x | - | 1.22x | - | 1.6x | 1.56x | - |
| PEG | - | -0.1x | -0.2x | 0.2x | 0.2x | 0.3x | 0.6x | -0x |
| Capitalization / Revenue | 6.41x | 3.83x | 1.52x | 1.53x | 1.98x | 1.48x | 1.33x | 1.1x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 1.48x | 1.33x | 1.1x |
| EV / EBITDA | 0x | 0x | 0x | 0x | 0x | 4.51x | 3.81x | 2.62x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -22.1x | -123x | 11.7x |
| EV / FCF | 0x | 0x | 0x | 0x | 0x | 6.44x | - | - |
| FCF Yield | 3.27% | 7.18% | 16.4% | 9.2% | 15.4% | 15.5% | - | - |
| Dividend per Share 2 | - | - | 0.7398 | - | - | - | - | - |
| Rate of return | - | - | 24.7% | - | - | - | - | - |
| EPS 2 | -0.41 | -0.73 | -0.85 | -0.62 | -0.39 | -0.2067 | -0.07 | 0.09 |
| Distribution rate | - | - | -87% | - | - | - | - | - |
| Net sales 1 | 60.01 | 61.47 | 63.07 | 56.62 | 55.5 | 58.44 | 65.03 | 78.65 |
| EBITDA 1 | 26.33 | 23.83 | 21.05 | 16.65 | 19.62 | 19.13 | 22.67 | 32.9 |
| EBIT 1 | -6.284 | -13.5 | -10.35 | -7.686 | -4.106 | -3.9 | -0.7 | 7.4 |
| Net income 1 | -13.12 | -23.6 | -27.53 | -19.66 | -12.43 | -5.47 | -2.164 | 3.1 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 11.853 | 7.263 | 2.991 | 2.731 | 3.515 | 2.791 | 2.791 | 2.791 |
| Nbr of stocks (in thousands) | 32,451 | 32,384 | 32,071 | 31,793 | 31,274 | 30,935 | - | - |
| Announcement Date | 3/17/22 | 3/16/23 | 3/14/24 | 3/13/25 | 3/12/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 22.42x | 0.25x | 14.09x | 0.42% | 102B | |
| 22.03x | 0.21x | 12.4x | 0.93% | 52.42B | |
| 33.84x | 2.54x | 22.92x | 1.79% | 20.85B | |
| 10.48x | 0.19x | 4.37x | 2.88% | 7.88B | |
| 12.68x | 0.9x | 7.44x | 3.13% | 6.83B | |
| 9.37x | 1.77x | 5.59x | 3.65% | 6.41B | |
| 5.36x | 0.08x | 2.36x | 5.53% | 5.97B | |
| 24.58x | 1.12x | 14.13x | 3.12% | 4.94B | |
| 12.9x | - | - | 2.57% | 3.79B | |
| Average | 17.07x | 0.88x | 10.41x | 2.67% | 23.45B | |
| Weighted average by Cap. | 21.69x | 0.55x | 13.36x | 1.2% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- HLS Stock
- HLTRF Stock
- Valuation HLS Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
